mProX™ Human ERBB2 Stable Cell Line

Product Information

Target Protein

ERBB2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MDA-MB-231; MCF7; NIH3T3; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research; Cardiovascular Research; Cancer Research; Reproductive Research

Related Diseases

Visceral Neuropathy, Familial, 2, Autosomal Recessive and Glioma Susceptibility 1. Among its related pathways are Drug resistance in ERBB2 KD mutants and Signaling by ERBB2 KD Mutants

Gene ID

2064

UniProt ID

P04626

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The ERBB2 gene encodes the protein known as receptor tyrosine-protein kinase erbB-2, which is typically found in cell membranes. The terms HER2 and CD340 are also commonly used to refer to the human protein. The human epidermal growth factor receptor (HER/EGFR/ERBB) family includes HER2. But unlike other ERBB family members, HER2 does not bind ligand directly. When HER2 concentrations are high, homodimerization occurs, or heterodimerization with another ERBB member resulting in HER2 activation. It has been demonstrated that this oncogene's amplification or overexpression is crucial to the onset and spread of several aggressive forms of breast cancer. For thirty percent of patients with breast cancer, the protein has emerged as a significant diagnostic and therapeutic target in recent years. The customized ERBB2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Ashley

I have been using the ERBB2 cell line for my research, and it has consistently provided reliable results. Sep 03 2021

chat Verified Customer

chat Thomas

The specificity and reproducibility of this ERBB2 cell line are impressive. I highly recommend it to fellow researchers. Jun 28 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Overexpression of ERBB2 promotes autophagy in breast cancer cells.

The overexpression of ERBB2 resulted in a minimum 40% increase in basal and amino acid starvation-induced levels of autophagy, as determined by LC3-II Western blotting, in the breast cancer cell lines MDA-MB-231 (ERBB2-negative) and MCF 7 (ERBB2-positive).

Ref: Chen, Yongqiang, et al. "Erb-b2 receptor tyrosine kinase 2 (ERBB2) promotes ATG12-dependent autophagy contributing to treatment resistance of breast cancer cells." Cancers 13.5 (2021): 1038.

Pubmed: 33801244

DOI: 10.3390/cancers13051038

Research Highlights

The scoring accuracy for ERBB2 IHC in the low range was subpar in this investigation utilizing the current standard ERBB2 IHC assay. In the actual world, this error could misidentify a large number of patients for T-DXd treatment.
Fernandez, Aileen I., et al. "Examination of low ERBB2 protein expression in breast cancer tissue." JAMA oncology 8.4 (2022): 1-4.
Pubmed: 35113160 DOI: 10.1001/jamaoncol.2021.7239

ErbB2 (or HER-2) is at the nexus of cancer and chronic heart failure due to its dual roles in tumor growth and the heart's physiological adaptive responses. Thus, activation of ErbB2 for heart failure therapy may induce malignancy, and ErbB2-targeted inhibitory therapy for cancer may cause ventricular dysfunction.
Vermeulen, Zarha, Vincent FM Segers, and Gilles W. De Keulenaer. "ErbB2 signaling at the crossing between heart failure and cancer." Basic research in cardiology 111 (2016): 1-14.
Pubmed: 27596216 DOI: 10.1007/s00395-016-0576-z